Moleac holds two educational symposia on the management of Traumatic Brain Injury
March 2019 Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic...
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset
More subjects on NeuroAiD™ improved to functional independence compared to placebo among subjects...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research...
NeuroAiD at ASEAN Neurological Association
Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) &...
NeuroAiD at Asia Pacific Stroke Conference
Renowned clinicians and researchers will present abstracts from the latest studies conducted on...
NeuroAiD at World Congress of Neurology
Moleac’s flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology...
NeuroAiD presentations at European Stroke Conference
NeuroAiD, Moleac’s main product, will be presented at the 26th European Stroke Conference on 24th...
NeuroAiD presentations at European Stroke Organisation Conference
NeuroAiD, Moleac’s main product, will be presented at the 3rd European Stroke Organisation...
Launch of NeuroAiD in Nigeria
Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be...
Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore
“Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a...
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study
Cerebrovasc Dis 2017; 43:36-42 Published by S. Karger AG, Basel This analysis from the CHIMES-E...
Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards
NeuroAiD™ has been named New Product Innovation of the Year by Frost & Sullivan. This award...
